PL2515886T3 - Przezskórny układ terapeutyczny do podawania rywastygminy lub jej pochodnych - Google Patents

Przezskórny układ terapeutyczny do podawania rywastygminy lub jej pochodnych

Info

Publication number
PL2515886T3
PL2515886T3 PL10790565T PL10790565T PL2515886T3 PL 2515886 T3 PL2515886 T3 PL 2515886T3 PL 10790565 T PL10790565 T PL 10790565T PL 10790565 T PL10790565 T PL 10790565T PL 2515886 T3 PL2515886 T3 PL 2515886T3
Authority
PL
Poland
Prior art keywords
derivatives
therapeutic system
transdermal therapeutic
administering rivastigmine
rivastigmine
Prior art date
Application number
PL10790565T
Other languages
English (en)
Inventor
Heike Prinz
Björn Schurad
Thomas Beckert
Kristina Linder
Original Assignee
Luye Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43383419&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2515886(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Luye Pharma Ag filed Critical Luye Pharma Ag
Publication of PL2515886T3 publication Critical patent/PL2515886T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/00051—Accessories for dressings
    • A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/00987—Apparatus or processes for manufacturing non-adhesive dressings or bandages
    • A61F13/00991—Apparatus or processes for manufacturing non-adhesive dressings or bandages for treating webs, e.g. for moisturising, coating, impregnating or applying powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T156/00—Adhesive bonding and miscellaneous chemical manufacture
    • Y10T156/10—Methods of surface bonding and/or assembly therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
PL10790565T 2009-12-22 2010-12-14 Przezskórny układ terapeutyczny do podawania rywastygminy lub jej pochodnych PL2515886T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09180413 2009-12-22
EP10154648 2010-02-25
EP10790565.5A EP2515886B1 (de) 2009-12-22 2010-12-14 Transdermales therapeutisches system zur verabreichung von rivastigmin oder dessen derivaten
PCT/EP2010/069654 WO2011076621A2 (de) 2009-12-22 2010-12-14 Transdermales therapeutisches system zur verabreichung von rivastigmin oder dessen derivaten

Publications (1)

Publication Number Publication Date
PL2515886T3 true PL2515886T3 (pl) 2018-08-31

Family

ID=43383419

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10790565T PL2515886T3 (pl) 2009-12-22 2010-12-14 Przezskórny układ terapeutyczny do podawania rywastygminy lub jej pochodnych

Country Status (16)

Country Link
US (1) US8962014B2 (pl)
EP (1) EP2515886B1 (pl)
JP (1) JP6083734B2 (pl)
KR (1) KR101674240B1 (pl)
CN (1) CN102711744B (pl)
AU (1) AU2010335309B2 (pl)
BR (1) BR112012017168B1 (pl)
CA (1) CA2785117C (pl)
CY (1) CY1120283T1 (pl)
DK (1) DK2515886T3 (pl)
ES (1) ES2670227T3 (pl)
MX (1) MX350357B (pl)
NO (1) NO2515886T3 (pl)
PL (1) PL2515886T3 (pl)
PT (1) PT2515886T (pl)
WO (1) WO2011076621A2 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150626A (en) 2009-10-30 2014-02-07 Ix Biopharma Ltd Fast dissolving solid dosage form
DE102010026903A1 (de) 2010-07-12 2012-01-12 Amw Gmbh Transdermales therapeutisches System mit Avocadoöl oder Palmöl als Hilfsstoff
RS54173B1 (en) * 2010-12-14 2015-12-31 Acino Ag TRANSDERMAL THERAPY SYSTEM FOR ACTIVE SUBSTANCE
EP2711002A4 (en) * 2011-05-20 2014-10-29 Sk Chemicals Co Ltd PLASTER WITH RIVASTIGMIN
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst COMPOSITIONS AND METHODS FOR TREATING SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE
EP2752188B1 (en) 2011-08-31 2020-05-06 Toyo Ink Sc Holdings Co., Ltd. Adhesive patch
EP2594261A1 (en) 2011-11-18 2013-05-22 Labtec GmbH Composition for transdermal administration of rivastigmine
DE102012000369A1 (de) 2012-01-11 2013-07-11 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System mit Cholinesterase-Hemmer
JP5093545B1 (ja) * 2012-02-28 2012-12-12 ニチバン株式会社 貼付剤
US20140083878A1 (en) * 2012-09-21 2014-03-27 Mylan Inc. Transdermal drug delivery device
CN103933018A (zh) * 2013-01-18 2014-07-23 江苏康倍得药业有限公司 一种透皮给药系统
US20180271800A1 (en) 2017-03-24 2018-09-27 E Ink California, Llc Microcell systems for delivering active molecules
JPWO2015174502A1 (ja) 2014-05-15 2017-05-25 ニチバン株式会社 リバスチグミンを含有する貼付剤のための包装体
CA2962059C (en) 2014-09-23 2020-03-24 Equistar Chemicals, Lp Polyolefin-based compositions, adhesives, and related multi-layered structures prepared therefrom
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
CA2977814A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
DE102015119789A1 (de) * 2015-11-16 2017-05-18 Denso-Holding Gmbh & Co. Korrosionsschutzzusammensetzung umfassend Polyisobutylene
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US10646454B2 (en) 2017-03-24 2020-05-12 E Ink California, Llc Microcell delivery systems including charged or magnetic particles for regulating rate of administration of actives
JP6972334B2 (ja) 2017-11-14 2021-11-24 イー インク カリフォルニア， エルエルシー 多孔性伝導電極層を含む電気泳動活性分子送達システム
WO2019201755A1 (en) * 2018-04-17 2019-10-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of solifenacin
JP7420797B2 (ja) 2018-05-29 2024-01-23 モーニングサイド ベンチャー インベストメンツ リミテッド 薬剤送達の方法及びシステム
KR20220074962A (ko) 2019-11-27 2022-06-03 이 잉크 캘리포니아 엘엘씨 전기 침식 밀봉층을 갖는 마이크로셀들을 포함하는 유익제 전달 시스템
WO2022093547A1 (en) 2020-10-29 2022-05-05 E Ink California, Llc Microcell systems for delivering hydrophilic active molecules
CN116322881A (zh) 2020-10-29 2023-06-23 伊英克加利福尼亚有限责任公司 用于递送有益剂的微单元系统

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
JPS63307818A (ja) 1987-06-08 1988-12-15 Sekisui Chem Co Ltd 経皮吸収貼付剤
JPH07116025B2 (ja) 1988-03-11 1995-12-13 積水化学工業株式会社 貼付剤
JP2693212B2 (ja) * 1989-03-28 1997-12-24 日東電工株式会社 疾患治療用テープ製剤
JPH08193030A (ja) * 1995-01-12 1996-07-30 Nitto Denko Corp エメダスチン貼付製剤
JPH10152434A (ja) 1996-09-26 1998-06-09 Nitto Denko Corp 経皮吸収型製剤
GB9800526D0 (en) 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
DE19814087A1 (de) * 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts Feuchtigkeitsaktivierbares therapeutisches System
DE19918106A1 (de) 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
DE10141652B4 (de) * 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
JP4394443B2 (ja) * 2001-10-17 2010-01-06 久光製薬株式会社 経皮吸収型製剤
JP4478757B2 (ja) 2002-04-19 2010-06-09 日東電工株式会社 ビソプロロール含有貼付剤
EP1830886B1 (en) * 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
CN1994290B (zh) * 2006-01-04 2011-03-16 上海医药工业研究院 卡巴拉汀透皮贴剂及其制备方法
CA2651596C (en) * 2006-05-08 2014-03-25 Teikoku Seiyaku Co., Ltd. Percutaneous absorption preparations of antidementia drugs
US9248104B2 (en) * 2006-08-17 2016-02-02 Core Tech Solutions, Inc. Transdermal methods and systems for treating Alzheimer's disease
JP2009022730A (ja) * 2007-06-18 2009-02-05 Kyoritsu Yakuhin Kogyo Kk 貼付剤

Also Published As

Publication number Publication date
EP2515886A2 (de) 2012-10-31
JP2013515025A (ja) 2013-05-02
CY1120283T1 (el) 2019-07-10
NO2515886T3 (pl) 2018-09-08
KR20120128606A (ko) 2012-11-27
MX350357B (es) 2017-09-05
KR101674240B1 (ko) 2016-11-08
WO2011076621A3 (de) 2012-02-09
ES2670227T3 (es) 2018-05-29
CA2785117A1 (en) 2011-06-30
DK2515886T3 (en) 2018-06-14
CN102711744B (zh) 2014-06-25
BR112012017168A2 (pt) 2018-05-02
BR112012017168B1 (pt) 2022-03-15
EP2515886B1 (de) 2018-04-11
CA2785117C (en) 2016-12-06
CN102711744A (zh) 2012-10-03
JP6083734B2 (ja) 2017-02-22
AU2010335309A1 (en) 2012-07-19
US20130261571A1 (en) 2013-10-03
WO2011076621A2 (de) 2011-06-30
PT2515886T (pt) 2018-05-23
US8962014B2 (en) 2015-02-24
AU2010335309B2 (en) 2015-08-20
MX2012007214A (es) 2012-09-12

Similar Documents

Publication Publication Date Title
PL2515886T3 (pl) Przezskórny układ terapeutyczny do podawania rywastygminy lub jej pochodnych
EP2560624A4 (en) THERAPEUTIC FORMULATION TO REDUCE THE SIDE EFFECTS OF MEDICATION
EP2299989A4 (en) STABILIZED TRANSDERMAL DRUG DISPENSING SYSTEM
EP2240236A4 (en) SKIN THERAPY SYSTEM
IL221007A (en) Pharmaceutical combinations for antiviral therapy
IL214402A0 (en) Transdermal pharmaceutical preparations
EP2392307A4 (en) DEVICE FOR CONTROLLING DOSAGE OF DRUG SOLUTION
ZA201303965B (en) Transdermal therapeutic system for administering an active substance
EP2424611A4 (en) DEVICE FOR TRANSDERMAL ADMINISTRATIONS
PT2464342E (pt) Novas formulações farmacêuticas para prevenir a utilização indevida de medicamentos
HK1215787A1 (zh) 用於治療疼痛的藥物組合
AP3250A (en) Tablets for combination therapy
ZA201005663B (en) Transdermal therapeutic system having stabilized membrane
ZA201403497B (en) Transdermal therapeutic system for administering fentanyl or analogue thereof
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
ZA200809004B (en) Autodestructive transdermal therapeutic system
ZA201301458B (en) Therapeutic agent for pain
PL385972A1 (pl) Kompozycja farmaceutyczna do leczenia chorób przyzębia
EP2486929A4 (en) ANTI-TUMOR THERAPEUTIC AGENT
ZA201201894B (en) Pharmaceutical combination for treating tumor
EP2460524A4 (en) MEDICAL COMPOSITION FOR IDE IONTOPHORESIS
EP2485719A4 (en) TRANSDERMAL THERAPEUTIC SYSTEM
EP2548580A4 (en) PHARMACEUTICAL FOR PSEUDOTRAINING THERAPY
EP2474325A4 (en) DRUG COMPOSITION FOR TREATMENT OF ANGIOGENESIS
IL200682A (en) A device for introducing drugs